Biotherapeutics Launches a New Fundraising Campaign
Tuesday, July 21, 2015
The Biotherapeutics (BTI) team traveled to BIO 2015 in Philadelphia June 16-19 to launch a new fundraising campaign that will allow the Company to complete IND-enabling TOX package, and initiate human clinical trials.
“BTI’s clinical candidate for Crohn’s disease (CD) is supported by data packages with strong animal pharmacology, validated MOA, promising safety profile, and impressive human translational data.” Said Dr. Carbo, Scientific Director.
“We are seeking $20M in Series A funding to complete IND-enabling toxicology studies, and initiate human clinical trials by 2016 and Phase IIa studies in the second half of 2017.” Said Dr. Bassaganya-Riera, President and CEO.
The BTI team will also attend the JP Morgan Healthcare Conference in January of 2016 to continue advancing its expansible drug discovery and development pipeline.